BBIO News and Press, BridgeBio Pharma Inc. From 12/25/25

2025-12-25 21:40:55 ET This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 11/14/2025. Please visit our ...

2025-12-23 12:41:26 ET Shares of BridgeBio ( BBIO ) have appreciated considerably this year. The stock has more than doubled since my first public article November 2024 and is up more than 160% since my February update . BridgeBio was one of my Top Picks in the Growth St...

2025-12-22 16:07:25 ET More on healthcare stocks My S&P 500 Prediction On Sector Outperformers And Laggards In 2026 Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026 IHI: A Passive ETF For Medical Device Exposure PACS G...

2025-12-17 12:29:56 ET Fast Facts About the Direxion Daily S&P Biotech Bull 3X ETF Read the full article on Seeking Alpha For further details see: LABU: The Risks And Rewards Of A Leveraged Biotechnology ETF

2025-12-13 22:45:00 ET The last three months have been a little more challenging for Alnylam Pharmaceuticals (ALNY), with slowing sales at a key rival raising concerns about the overall health of the critical transthyretin amyloidosis (or TTR) space, particularly with more competition l...

2025-12-11 05:06:16 ET from Bernstein issued a price target of $94.00 for BBIO on 2025-12-11 09:54:18. The adjusted price target was set to $94.00. At the time of the announcement, BBIO was trading at $72.7. The overall price target consensus is at $83.71 with high price...

PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in fires...

2025-11-23 07:04:57 ET Introduction BridgeBio (BBIO) has risen roughly 90% since I initiated coverage back in April of 2025. It quickly became the largest position in my portfolio and was the primary driver of my outperformance this year.... Read the full article on Seekin...

2025-11-10 20:21:32 ET BridgeBio Pharma, Inc. (BBIO) UBS Global Healthcare Conference 2025 November 10, 2025 1:15 PM EST... Read the full article on Seeking Alpha For further details see: BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript

- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: 59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared to patients initially randomized to placebo in the ATTRibute-CM study 69% risk r...